{
    "2018-02-22": [
        [
            {
                "time": "2017-10-01",
                "original_text": "Eli Lilly’s New Product Portfolio in 4Q17",
                "features": {
                    "keywords": [
                        "new product",
                        "portfolio",
                        "4Q17"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2017-10-01",
                "original_text": "A Look at Eli Lilly’s Neuroscience Portfolio in 4Q17",
                "features": {
                    "keywords": [
                        "neuroscience",
                        "portfolio",
                        "4Q17"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2017-10-01",
                "original_text": "Eli Lilly’s Oncology Portfolio in 4Q17",
                "features": {
                    "keywords": [
                        "oncology",
                        "portfolio",
                        "4Q17"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2017-10-01",
                "original_text": "How Eli Lilly’s Cardiovascular Portfolio Performed in 4Q17",
                "features": {
                    "keywords": [
                        "cardiovascular",
                        "portfolio",
                        "performance",
                        "4Q17"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2017-10-01",
                "original_text": "Comparing Eli Lilly’s Business Segments in 4Q17",
                "features": {
                    "keywords": [
                        "business segments",
                        "comparison",
                        "4Q17"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2017-10-01",
                "original_text": "Eli Lilly’s Human Pharmaceutical Portfolio in 4Q17",
                "features": {
                    "keywords": [
                        "human pharmaceutical",
                        "portfolio",
                        "4Q17"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2017-10-01",
                "original_text": "A Look at Eli Lilly’s 4Q17 Revenue",
                "features": {
                    "keywords": [
                        "revenue",
                        "4Q17"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2017-10-01",
                "original_text": "United Therapeutics (UTHR) Q4 Earnings Decline on High Costs",
                "features": {
                    "keywords": [
                        "earnings decline",
                        "high costs",
                        "Q4"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}